TriSalus Life Sciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.9M | $13.2M | $11.6M | $11.2M | $9.2M | $8.3M | $7.3M |
| Cost of Revenue | $1.5M | $1.2M | $1.8M | $1.9M | $1.8M | $1.5M | $1.2M | $1.0M |
| Gross Profit | $9.9M | $7.7M | $11.4M | $9.7M | $9.4M | $7.7M | $7.0M | $6.3M |
| Gross Margin | 86.8% | 86.2% | 86.7% | 83.5% | 83.9% | 83.7% | 85.3% | 86.3% |
| Operating Expenses | ||||||||
| Research & Development | $3.1M | $3.2M | $3.1M | $5.2M | $3.7M | $3.0M | $3.0M | $4.2M |
| SG&A Expense | $5.2M | $5.5M | $3.6M | $6.7M | $5.9M | $5.2M | $4.7M | $4.7M |
| Operating Income | $-9.8M | $-8.4M | $-3.3M | $-9.0M | $-7.3M | $-7.3M | $-7.6M | $-8.7M |
| Operating Margin | -86.0% | -94.5% | -24.8% | -77.9% | -65.4% | -79.9% | -91.8% | -118.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-9.2M | $1.5M | $-9.8M | $-10.8M | $-8.3M | $-10.4M | $-10.1M | $-2.4M |
| Income Tax Expense | $4.0K | $4.0K | $0 | $5.0K | $-3.0K | $5.0K | $-1.0K | $-3.0K |
| Net Income | $-9.2M | $1.5M | $-9.8M | $-10.8M | $-8.3M | $-10.4M | $-10.1M | $-2.4M |
| Net Margin | -80.5% | 17.3% | -73.9% | -93.5% | -73.9% | -113.2% | -122.4% | -32.6% |
| EPS (Basic) | $-0.16 | $0.03 | $-0.22 | $-0.32 | $-0.27 | $-0.39 | $-0.38 | $-0.04 |
| EPS (Diluted) | $-0.16 | $0.03 | $-0.22 | $-0.32 | $-0.27 | $-0.39 | $-0.38 | $-0.04 |
| Shares Outstanding (Basic) | 58.3M | 51.5M | 37.9M | 129.2M | 32.9M | 28.5M | 25.3M | 79.5M |
| Shares Outstanding (Diluted) | 58.3M | 52.3M | 37.9M | 129.2M | 32.9M | 28.5M | 25.3M | 79.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |